BioSpace News Archive

Three oral presentations accepted on new clinical and preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 23rd annual meeting Completed two collaboration agreements to reinforce technological leadership in lentiviral gene therapy Raised $100 million in gross proceeds from follow-on stock offering in February 2020, strengthening our balance sheet with more than two years of cash runway

ADX-629 Expected to Begin Phase 2 Clinical Trials in COVID-19 Respiratory Compromise, Atopic Asthma, and Psoriasis in 2020 Type C Meeting Scheduled with FDA to Discuss Remaining NDA Requirements for Reproxalap in Dry Eye Disease Results from Phase 3 INVIGORATE Trial of Reproxalap in Allergic Conjunctivitis Expected in First Half of 2021 Cash Runway Extended into 2022 Management to Host Conference Call at 8:00 a.m. ET To

-- ME-401 global alliance with Kyowa Kirin executed, $100M in upfront payment and MEI eligible to receive up to an additional $582.5M in milestones -- -- Fast Track designation granted by US FDA to ME-401 for treatment of adult patients with relapsed or refractory follicular lymphoma --

Apple® announced it is awarding $10 million from its Advanced Manufacturing Fund to COPAN Diagnostics, a market leader in sample collection kits that play a critical role in COVID-19 testing.

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced its financial results for the first quarter ended March 31, 2020, and provided a corporate update.

On track to submit an IND or IND-equivalent for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020; plans to dose first patient in 2H 2020

Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, reported financial results for the quarter ended March 31, 2020 and provided an update on its product pipeline and corporate activities.

Ovid Therapeutics Inc., a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, announced positive topline results from the signal-finding Phase 2 ROCKET trial of OV101, a novel delta -selective GABAA receptor agonist, in males with Fragile X syndrome.

Palatin Technologies, Inc. will announce its third quarter fiscal year 2020 operating results on Tuesday, May 12, 2020 before the open of the U.S. financial markets.

MGTA-117 ADC clinical candidate for immune and blood system reset has demonstrated broad therapeutic index; on track for initial clinical data in 2021